Revolution Medicines, Inc.

What they do

Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies for patients with RAS-addicted cancers. Its pipeline includes oral RAS(ON) multi-selective and mutant-selective inhibitors, with lead candidate daraxonrasib being developed for pancreatic and lung cancers. The company has no products approved for commercial sale and has not generated any revenue from product sales.

Revenue drivers

• Daraxonrasib (RAS(ON) multi-selective inhibitor) — Lead candidate; an NDA for previously treated metastatic pancreatic cancer has been accepted by the FDA; potential first commercial product, but no revenue yet.
• Elironrasib and zoldonrasib (RAS(ON) inhibitors) — Combination data in first-line non-small cell lung cancer support registrational studies; potential future revenue sources, but still in clinical development.

Recent performance

For the year ended December 31, 2025, net loss was $1.1 billion, compared to $600.1 million in 2024 and $436.4 million in 2023. Operating cash flow was negative $897.7 million in 2025. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $3.9 billion, with total assets of $4.32 billion and shareholder equity of $2.61 billion. The company reported zero revenue in recent quarters. In August 2026, the FDA accepted the NDA for daraxonrasib for previously treated metastatic pancreatic cancer, and the company launched an Expanded Access Program that has served over 2,000 patients.

Strategy

The company is prioritizing regulatory advancement and commercialization of daraxonrasib in pancreatic cancer, including U.S. launch readiness and global regulatory submissions. It is also expanding daraxonrasib into earlier lines of therapy through Phase 3 studies RASolute 303 and 304. In lung cancer, it is advancing elironrasib and zoldonrasib combinations toward registrational studies. The company continues to invest in its RAS-targeted pipeline across multiple indications.

Risks

• No approved products or revenue — The company has no commercial products and has never generated product revenue, relying on funding from equity sales and other agreements.
• Significant ongoing losses — Net losses have grown to $1.1 billion in 2025, and the company expects to incur losses for at least the next several years.
• Clinical and regulatory uncertainty — Daraxonrasib and other candidates require additional development, and there is no assurance of regulatory approval or commercial success.
• Need for additional capital — The company's operations consume substantial cash, and it may need to raise additional financing to fund future development and commercialization.

Outlook

Management expects continued losses and significant R&D expenses as it advances daraxonrasib through regulatory review and launches, if approved. The company is building global commercialization capabilities and expanding its pipeline in pancreatic and lung cancers. It has cash of $3.9 billion as of June 30, 2026, which it expects to use to fund operations, but no specific runway guidance was provided.